Assistant Professor of Urology, University Colorado

Urology

Dr. Paul D. Maroni practices Urology. He graduated from University of Illinois College of Medicine. He received 2 awards: "Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Paul D. Maroni is a published doctor. He has 34 publications published. The most current publication "Signal transduction pathway of prolactin in rat liver." Paul Maroni is registered with Medicare.

Publications

---

• Survival Outcomes of Dose-Escalated External Beam Radiotherapy (DE-EBRT) Versus Combined Brachytherapy for Intermediate- and High-Risk Prostate Cancer Using the Nation...
• Inhibition of Lipid Oxidation Increases Glucose Metabolism and Enhances 2-Deoxy-2-[(18)F]Fluoro-D-Glucose Uptake in Prostate Cancer Mouse Xenografts.
• The impact of definitive local therapy for lymph node-positive prostate Cancer: a population-based study.
• In germ cell Cancer, are we at the end of the chemotherapy era? Maybe--and we are certainly at the end of the RCT era.
• Priapism Induced by Boceprevir-CYP3A4 inhibition and Alpha-Adrenergic Blockade.
• Clinical-pathologic correlation between transperineal mapping biopsies of the Prostate and three-dimensional reconstruction of Prostatectomy specimens.
• Bridging the transition from Cancer patient to survivor: Pilot study results of the Cancer Survivor Telephone Education and Personal Support (C-STEPS) program.
• Hopes and dreams for quality improvement in radical Prostatectomy.
• Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and role of HDACs.
• Signal transduction pathway of prolactin in rat liver.
• The MAP kinase cascades are activated during post-ischemic liver reperfusion.
• Hyperthermia induces gene expression of heat shock protein 70 and phosphorylation of mitogen activated protein kinases in the rat cerebellum.
• Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive ...
• The role of inflammation and infection in prostate Cancer: Importance in prevention, diagnosis and treatment.
• Oxalate exposure provokes HSP 70 response in LLC-PK1 cells, a line of Renal epithelial cells: protective role of HSP 70 against oxalate toxicity.
• Do tumor characteristics and prognostic factors differ between subsequent rounds of PSA screening for prostate Cancer?
• Linear growth after enterocystoplasty in children and adolescents: a review.
• Focal adhesion kinase controls aggressive phenotype of androgen-independent prostate Cancer.
• Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma.
• Validation of the modified american urological association symptom score.
• Assessment of men before androgen deprivation therapy.
• A man with changes in the urinary Bladder: benign metaplasia or adenocarcinoma?
• Oxidative stress in prostate Cancer.
• Words of wisdom. Re: mortality results from the Göteborg randomised population-based prostate-Cancer screening trial.
• Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate Cancer: regulation of MMP 9 by PDEF.
• The benefits of early androgen blockade.
• Screening for prostate Cancer in 2006: PSA in the 21st century.
• Alpha-9 nicotinic acetylcholine receptor immunoreactivity in the rodent vestibular labyrinth.
• Oxalate toxicity in cultured mouse inner medullary collecting duct cells.
• Long-term dietary habits affect soy isoflavone metabolism and accumulation in prostatic fluid in caucasian men.
• Surgical management of prostate Cancer: optimizing patient selections and clinical outcome.
• p42/p44 Mitogen-activated protein kinase signal transduction pathway: a novel target for the treatment of hormone-resistant prostate Cancer?
• Effects of oxalate on IMCD cells: a line of mouse inner medullary collecting duct cells.

Schools

---

• UNIVERSITY OF ILLINOIS COLLEGE OF MEDICINE

• UNIVERSITY OF COLORADO AT DENVER

• University Of Colorado

• Indiana University School Of Medicine Program

• University Of Virginia

Procedures Preformed

---

• Abdominal Surgery
• AdRenalectomy
• Cystectomy
• Cystometry
• View All

Conditions Treated

---

• Balanoposthitis
• Bladder Cancer
• Bladder Infection
• Bladder Stones
• View All

Doctors Specialties

---

• Urology

Accepted Insurances

---

Awards

---

• Regional Top Doctor
• CMS Meaningful Use Stage 1 Certification

Education

---

• University of Colorado
• University of Illinois College of Medicine

Hospital

---

• University of Colorado Hospital

Drug Facts

---

NPI NUMBER		1235199688
NPPES Provider LastName		MARONI
NPPES Provider FirstName		PAUL
NPPES Provider ZIPCode		800452545
NPPES Provider State		CO
Specialty Description		Urology
Total Claim Count		298.0
Distinct Opioid Count		1.0
Opioid Claim Count		11.0
Percent Opioid Claims		3.69

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1235199688
Last Name Of The Provider	MARONI
First Name Of The Provider	PAUL
View All

Similar Doctors

---

	Dr. Daniel Theodorescu, MD This Doctor is OpenDoctor Recommended.
	Dr. Elward D. Crawford, MD This Doctor is OpenDoctor Recommended.
	Dr. Louis N. Ashkar, MD
	Dr. Duncan T. Wilcox, MD This Doctor is OpenDoctor Recommended.
	Dr. Randall B. Meacham, MD This Doctor is OpenDoctor Recommended.
	Dr. Brian T. Caldwell, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert J. Larke, MD
	Dr. Joshua D. Spendlove, MD This Doctor is OpenDoctor Recommended.
	Dr. Trevor T. Wild, MD This Doctor is OpenDoctor Recommended.
	Dr. Nicholas J. Westfall, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog